Site Neutral Payments Explained for ASC Owners and Hospital CFOs
Medicare's CY2026 site neutral rule just added five hundred sixty procedures to the ASC covered list, and the margin impact depends entirely on whether you run the numbers before or after you schedule the case. We break down exactly what changed, what stayed the same, and what hospital CFOs and ASC owners should each be doing this quarter.
Chapters:
0:06 Cold Open
0:28 What Site Neutral Actually Means
1:26 What Changed in the CY2026 Rule
2:36 What It Means for Hospital CFOs
3:49 What It Means for ASC Owners
5:04 The Gap Between the Rule and Your Pro Forma
6:17 What To Actually Do This Quarter
7:17 Close
Free guide, The 2027 ASC State of the Union: https://sigmatic.ai/guide
Book a free consultation: https://sigmatic.ai/contact
#asc #surgerycenter #ambulatorysurgery #healthcarefinance #orutilization #sitenural #medicarereimbursement
Chapters
- 00:06 Cold Open
- 00:28 What Site Neutral Actually Means
- 01:26 What Changed in the CY2026 Rule
- 02:36 What It Means for Hospital CFOs
- 03:49 What It Means for ASC Owners
- 05:04 The Gap Between the Rule and Your Pro Forma
- 06:17 What To Actually Do This Quarter
- 07:17 Close
Transcript
Read the full transcript Every episode is transcribed, searchable, and quotable. Plain text
Sigmatic: Here's a sentence that should get your attention if you run a surgery center or sit in a hospital CFO's chair. Not a typo. Not a glitch. That's just what happens when a rule moves faster than a payer's rate table. So let's walk through it together, because there's a real answer, and it's not complicated, it's just work.
Sigmatic: Site neutral payment is the policy direction where Medicare pays the same rate for the same procedure no matter where you do it. Historically, Medicare paid more for a procedure done in a hospital outpatient department than in an ASC, and more again for the same thing done as an inpatient. Site neutral is the slow grind toward collapsing that gap. The twenty twenty-six rule didn't finish that work, and I want to be straight with you about how narrow the actual change was. It touched one specific thing, drug administration services in certain off campus hospital departments, which now get paid at the physician fee schedule rate instead of the higher hospital rate. That's it. That's the technical change. But the direction behind it is the real story, because every rule cycle that treats the location of care as less important to the payment amount is a rule cycle that makes the case for doing more procedures in an ASC stronger. The five hundred sixty procedures added to the covered list are the visible part of that same logic playing out.
Sigmatic: Let me give you the five things that actually moved, because this is the part you build a budget around. First, payment rates for ASCs and hospital outpatient departments went up about two point six percent for centers that meet their quality reporting requirements. Second, five hundred sixty surgical procedures and thirty five ancillary services got added to the ASC covered list, and two hundred seventy one of those codes came straight off the inpatient only list. Third, the inpatient only list itself is being phased out over three years starting in twenty twenty-six, with musculoskeletal procedures going first. Fourth, that site neutral change on drug administration we just talked about. If your center misses its reporting requirement, you don't just get a smaller increase, you lose two full percentage points off the annual update. That's the enforcement mechanism sitting quietly underneath that two point six percent number. And the inpatient only phase out isn't a maybe, it's scheduled. Every year for three years, more procedures move, and each one needs a contribution margin calculation before it lands on your schedule, not after.
Sigmatic: If you're a hospital CFO, site neutrality is squeezing the exact procedures where an ASC was already built to compete. Total joints, GI cases, the stuff that used to run through your hospital outpatient department at a nice premium. That premium is shrinking, procedure by procedure, rule cycle by rule cycle. They're trying to own ASC capacity instead. About thirty eight percent of ASC revenue already sits outside pure physician ownership, in hospital, corporate, or joint venture structures, with sixty two percent still physician owned. A joint venture turns a shrinking hospital outpatient margin into a share of a growing ASC one. I'll put the links in the description if you want the full reimbursement comparison between the two settings. The timing question for a CFO isn't whether to respond to this, it's whether to build, buy, or partner before the next three rule cycles finish moving the inpatient only list, or after. And that timing isn't free. Thirty five states plus the District of Columbia still run some form of certificate of need program, and several of them exempt ASCs or apply a lighter review. A certificate of need state adds months to a build or buy decision that a non certificate of need state doesn't have to think about.
Sigmatic: Now if you run the ASC, here's the thing nobody says loudly enough. A newly covered procedure with no commercial rate attached is not revenue. It's a negotiation. Most commercial payers price ASC procedures as a multiple of the Medicare rate, and a code that just came off the inpatient only list often has no commercial ASC rate on file at all. The center that walks into that negotiation with an actual cost per case gets a real rate. The center that walks in with a volume estimate gets whatever number the payer already had sitting in a drawer. Before you add any of these newly covered procedures to a surgeon's block, there are three questions worth asking out loud. What does this procedure actually cost your center, by direct supply, implant, and labor minutes, not by some national average supply ratio that has nothing to do with your invoices. What does each payer in your mix currently pay for it, and is that a negotiated ASC rate or an unpriced Medicare multiple that needs a phone call. And what contribution margin does it clear once both of those numbers are real, and does that margin justify taking block time away from something already on your schedule. The links are in the blog, click over and check them out if you want our full breakdown on costing a case before you price it.
Sigmatic: Here's the mistake we see most often. Treating the covered list expansion like it's already money in the bank. It's not. It's addressable market. The twenty twenty-six rule made a wider range of procedures payable in an ASC setting. It did not make your supply chain, your staffing model, or your payer contracts ready to deliver those procedures at a margin. A procedure that looks profitable at the national average supply ratio can be underwater once you check it against your center's actual implant invoice. The only way to know before you schedule the first case is to run your own numbers, not the rule's numbers. And the same logic holds on the revenue cycle side. A new covered procedure with no commercial rate on file also has no prior authorization history and no denial pattern yet. You want to be tracking that from the first case, not the fiftieth, against the same denial rate and days in AR benchmarks you already hold the rest of your schedule to. The links are below, I will put them in the show notes if you want to see where those thresholds should sit. And since every new procedure competes for the same block minutes as everything already on your schedule, your operating room utilization discipline matters more with each covered list expansion, not less.
Sigmatic: So here's what we'd actually do, starting now, not after the next rule cycle. First, list out every procedure your surgeons are already doing in a hospital setting that moved onto the ASC covered list in twenty twenty-six, and cost each one using real consumption and implant invoices before you schedule a single case. Not estimates. Actual numbers. Second, pull the commercial rate on file for each of those procedures, payer by payer. Anywhere there's no rate, or the rate is just an unpriced Medicare multiple, put that payer on your contracting list before the first patient gets booked, not after. And third, keep an eye on the twenty twenty-seven final rule when it publishes in November, and check it against the budget you're building right now. A conversion factor change, another covered list addition, or the next phase of the inpatient only phase out can move a number you already built a whole pro forma around. This is a yearly discipline now, not a one time project.
Sigmatic: Site neutral payments are going to keep arriving every November for years, and the centers that do well with this aren't the ones with the fanciest forecast, they're the ones who treat every rule cycle as a costing exercise instead of a headline. That's really the whole episode in one sentence. If you want help running that exercise on your own center, and you want your A S C to actually be more profitable instead of just busier, book a free consultation with us at sigmatic dot A I. We'll sit down with your own numbers, your own payer mix, your own implant invoices, and show you where the margin really is. And grab our free guide, The twenty twenty-seven A S C State of the Union, while you're at it. The links are in the show notes. Thanks for spending this time with us on The Margin, and we'll see you next episode.
After the episode
Want a more profitable ASC?
Book a free 30-minute consultation on your own numbers, or leave your email and we will send the 2027 guide first.
Make your ASC more profitable.
A free 30-minute consultation on your own numbers: where the margin is, what to fix first. No obligation.